CDC-RFA-JG-26-0142: Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control-GHC notices from 2026.
Centers for Disease Control-GHC offered grants to any type of organization. It expected to make about 2 awards. Applications closed on September 16, 2026.
From the official notice on Grants.gov, last changed August 17, 2026. Checked November 7, 2026.
- Expected awards2
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | August 17, 2026 |
|---|---|
| Deadline | September 16, 2026 |
| Archived by Grants.gov | October 16, 2026 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (61% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $6,000,000 for Year 1, subject to the availability of funds. This NOFO supports India"s National AIDS Control Organization (NACO), Central Tuberculosis Division (CTD), and other departments in the Ministry of Health and Family Welfare (MoHFW). The goal is to enhance systems that accelerate and sustain epidemic control, in line with the National AIDS Control Program (NACP)-VI and the National TB Elimination Program (NTEP), while working to eradicate HIV and TB as public health threats. The NOFO aims to transition essential services to local ownership and foster cooperation with interest holders at all levels. To accomplish this goal you should incorporate innovative and evidence-based strategies to:• Prevent new infections.• Facilitate early case detection.• Ensure seamless linkage to care.• Promote treatment adherence.• Achieve viral suppression. Key activities include:• Closing gaps in HIV and TB testing and treatment.• Delivering integrated services for HIV and co-morbidities.• Strengthening program cooperation and ownership to enhance national efforts.• Improving prevention, detection, and response to infectious diseases. Advancing innovative HIV and TB service delivery under local leadership will create a sustainable framework for epidemic control that aligns with U.S. global health priorities, ultimately saving lives and bolstering global health security.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Who has won Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally grants before
From fiscal 2021 to 2025, Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally (93.494) awarded $18.4 million across 14 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Baylor College of Medicine | Texas | 1 | $5.3 million |
| United Nations Office for Project Services | 1 | $4.2 million | |
| Path | Washington | 1 | $2.7 million |
| World Health Organization, Somalia | 1 | $1.3 million | |
| Union Internat Tuberculose Maladie Respi | 1 | $1.3 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-JG-26-0142 still open?
No. It closed on September 16, 2026.
Who can apply for Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India?
Centers for Disease Control-GHC accepted applications from any type of organization.
What is the deadline for Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India?
Closed September 16, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)